Real World Evidence (RWE) of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Poland (HCV RWE PMOS)
Phase of Trial: Phase IV
Latest Information Update: 07 Apr 2017
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors AbbVie
- 03 Apr 2017 Status changed from active, no longer recruiting to completed.
- 31 Oct 2016 Planned number of patients changed from 400 to 100.
- 31 Oct 2016 Planned End Date changed from 1 Apr 2017 to 1 Mar 2017.